In 2021, the Total Profit of China's Pharmaceutical Industry will Exceed 700 Billion Yuan, a Year-on-year Increase of 67.3%
On May 10, at the press conference of the National Development and Reform Commission on the "14th Five-Year Plan for Bioeconomic Development", Zhou Jian, deputy director of the Consumer Products Industry Department of the Ministry of Industry and Information Technology, introduced that in 2021, the main economic indicators of my country's pharmaceutical industry will show rapid growth.
Specifically, in 2021, the added value of the pharmaceutical industry will increase by 23.1% year-on-year, and the growth rate will increase by 15.3 percentage points over the same period of the previous year, which is 13.5 percentage points higher than the overall growth rate of all industries. The proportion of the added value of the pharmaceutical industry in the total industrial added value continued to rise, accounting for 4.1%, and its role in stabilizing industrial economic growth was further enhanced. The operating income was 3,370.75 billion yuan, a cumulative year-on-year increase of 18.7%, an increase of 11.4 percentage points over the same period of the previous year, and the growth rate reached a new high in the past five years. The total profit achieved was 708.75 billion yuan, a year-on-year increase of 67.3%.
2026-09-06
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China's Ibuprofen Export Performance, First Half of 2026
-
Germany Passes Healthcare Reform, Multinational Drugmakers Face 15.5% Mandatory Discount
-
The relationship between Digital Transformation and Work- Life Balance in the Egyptian Pharmaceutical Industry
-
What Does the Future Hold for the Anti-Obesity Drug Market in 2024?
-
Hengrui entered the top 20 for the first time. How big is the gap between Chinese and American pharmaceutical companies?
-
The State Food and Drug Administration accepted the marketing application of Ditze Pharma suvortinib
-
Jimin's innovative polycystic kidney disease innovative drug was approved by the FDA for clinical trials
-
Another giant may be broken up
-
NASH is on the verge of a new drug, and the 40-year black hole is finally shining a light
-
Novo Nordisk Shanghai and ShanghaiPharmaceutical Holdings sign a contract to make another breakthrough incooperation
Recommend Reading
-
Ukraine Strikes Russia’s Ryazan Refinery Again, Setting 17-Million-Tonne Facility Ablaze
-
Wanhua Chemical Raises Southeast Asia MDI and TDI Offers by $200 per Tonne
-
Sekisui Specialty Chemicals Has Announced a Global Price Increase
-
EU mulls expanding tariff scope on Chinese chemicals, sector-wide measures in the pipeline
-
Do You Know the Food Zero Additives?
-
July China Phenol Market Trended Upward with Fluctuations
-
MTBE Market Trend Shows Significant Decline in China
-
In July, the Chinese anhydrous hydrogen fluoride market showed an upward trend
-
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
Premium Global Chemical Sourcing Requests (27-29July, 2026)
- Hot Searches
- tci 4-fluorobenzaldehyde price
- rad 150 for sale
- how much does kerosene cost a gallon
- calcium sulfate compound
- 30 mg tirzepatide peptide for sale
- alpha olefin sulfonate price
- losartan potassium vs losartan
- tirzepatide peptide for sale
- tergitol 91-6
- petrol coke price
- meg pricing
- propene price